Form 4: Alzamend Neuro Director Milton C. Ault III Reports Stock Purchase

Director Milton C. Ault III reports purchasing 75 shares of Alzamend Neuro, Inc. stock at $2.75 per share on August 6, 2024.

Summary

• On August 6, 2024, Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc. [ALZN], purchased 75 shares of common stock at a price of $2.75 per share.
• Following the transaction, Mr. Ault indirectly owns 77,268 shares through Ault Lending, LLC, 99,619 shares through Ault Life Sciences, Inc., and 549 shares through Ault Life Sciences Fund, LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. The purchase could be seen as slightly positive, but without more context, it's difficult to assess the overall impact.

Positives

• The purchase of shares by a director could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's stock.

Stakeholder Impact

• The stock purchase by a director may have a minor positive impact on shareholder confidence.

Key Dates

Keywords

Alzamend Neuro, ALZN, Milton C. Ault III, stock purchase, director, Form 4, beneficial ownership, Ault Lending LLC, Ault Life Sciences Inc, Ault Life Sciences Fund LLC